- Home
- IRD vs AIRT Comparison
IRD vs AIRT Comparison
Compare IRD & AIRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- AIRT
- Stock Information
- Founded
- IRD 2018
- AIRT 1980
- Country
- IRD United States
- AIRT United States
- Employees
- IRD N/A
- AIRT N/A
- Industry
- IRD
- AIRT Air Freight/Delivery Services
- Sector
- IRD
- AIRT Consumer Discretionary
- Exchange
- IRD NYSE
- AIRT Nasdaq
- Market Cap
- IRD 38.8M
- AIRT 43.5M
- IPO Year
- IRD N/A
- AIRT N/A
- Fundamental
- Price
- IRD $0.99
- AIRT $16.99
- Analyst Decision
- IRD Strong Buy
- AIRT
- Analyst Count
- IRD 2
- AIRT 0
- Target Price
- IRD $7.00
- AIRT N/A
- AVG Volume (30 Days)
- IRD 206.9K
- AIRT 2.9K
- Earning Date
- IRD 05-15-2025
- AIRT 06-25-2025
- Dividend Yield
- IRD N/A
- AIRT N/A
- EPS Growth
- IRD N/A
- AIRT N/A
- EPS
- IRD N/A
- AIRT N/A
- Revenue
- IRD $10,992,000.00
- AIRT $298,215,000.00
- Revenue This Year
- IRD $22.00
- AIRT N/A
- Revenue Next Year
- IRD $100.89
- AIRT N/A
- P/E Ratio
- IRD N/A
- AIRT N/A
- Revenue Growth
- IRD N/A
- AIRT 3.36
- 52 Week Low
- IRD $0.65
- AIRT $14.56
- 52 Week High
- IRD $2.18
- AIRT $30.60
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- AIRT 55.61
- Support Level
- IRD N/A
- AIRT $15.04
- Resistance Level
- IRD N/A
- AIRT $16.14
- Average True Range (ATR)
- IRD 0.00
- AIRT 0.47
- MACD
- IRD 0.00
- AIRT 0.16
- Stochastic Oscillator
- IRD 0.00
- AIRT 97.99
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.